evaluated the function of CD19 CAR-modified CD8+ Tscm cells in a B-ALL mouse model and found that these CAR-T cell products mediated a prolonged antitumor response and increased survival compared to CD8+ T cells generated CD19 CAR-T cells (38). This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.